While use of aspirin has been previously thought to be associated with a reduced risk of ovarian cancer due to inhibition of NF-κB and inflammatory pathways, epidemiologic data also suggests a role for post-diagnostic use of aspirin and other NSAIDs with anti-platelet activity in decreasing production of thromboxane, a mediator of platelet aggregation, and mitigating disease progression and survival [41,42,43,100,101,102,103,104]. The gene discussed is NFKB1; the disease is ovarian cancer.